Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ABBV and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ABBV and 80,000+ other tickers.
See exactly how ABBV's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ABBV and 80,000+ other tickers.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and…
Glenview Trust Co purchased a new position in AbbVie Inc. (NYSE: ABBV) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 421,257 shares of the company's stock, valued at approximately $91,619,000. A number of other hedge funds and other institutional
Dearborn Partners LLC acquired a new position in shares of AbbVie Inc. (NYSE: ABBV) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 128,402 shares of the company's stock, valued at approximately $27,926,000. AbbVie comprises about 1.3%
Empowered Funds LLC reduced its position in AbbVie Inc. (NYSE: ABBV) by 10.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 202,359 shares of the company's stock after selling 24,477 shares during the period. Empowered Funds LLC's holdings
BNP Paribas lifted its position in AbbVie Inc. (NYSE: ABBV) by 16.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 79,596 shares of the company's stock after buying an additional 11,318 shares during the period. BNP Paribas' holdings
Braun Stacey Associates Inc. raised its holdings in AbbVie Inc. (NYSE: ABBV) by 3.9% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 87,528 shares of the company's stock after purchasing an additional 3,269 shares during the quarter. Braun Stacey Associates Inc.'s